ARTICLE | Clinical News
Grazoprevir/elbasvir: Phase III data
November 23, 2015 8:00 AM UTC
Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Grazoprevir/elbasvir ( MK-5172/MK-8742) Business: Infectious Molecular target: HCV NS3/4A protease complex; HCV NS5A protein Description: Fixed...